gross margin central cl invest case year miss
quarter spark bigger pictur question decad tout gross margin
key leverag point provid fund reinvest growth colgat
struggl make last progress front past year although
would note fx input cost environ volatil think
unwis draw structur conclus one quarter result understand
trigger question around compani longer term abil sourc ampl
reinvest dollar return dd local currenc earn growth algorithm
time improv revenu perform prior troubl spot seem
entir overlook dialogu even though isnt colgat first
reinvest year would argu first cohes
coordin approach reinvigor core franchis explor new channel
granular categori opportun expand adjac time around
seem yield invest point perform hill
relaunch yield hsd revenu growth averag ttm latam post
organ sale growth balanc volum price wed also point organ
sale volum growth china india russia three key market colgat
suffer share loss sale declin local special competitor
still north america challeng exclud new skin
busi may trend rate market growth aggreg
math half organ sale growth may account
pca eltamd appreci discuss total fare sinc
relaunch domest share bp versu previous
downsiz total expensive/oz
line crest health primari competitor multi-benefit segment
look wed expect see similar revamp core franchis oral
particularli price-ti key part go-forward strategi
cl quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
execut strategi remark market share
leav us construct compani potenti
reacceler growth bolster profit
also expect share continu
bake degre takeout premium near
assum cl share trade premium
large-cap stapl peer group trade
premium market ep
estim
assum cl share trade premium
large-cap stapl peer group trade
premium market ep estim
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
friday colgat report ep compar consensu
barclay research
stock sentiment neutral neg head earn
surpris see result taken portli cl vs flat xlp though
bar certainli move higher stapl fundament perform quarter
certainli without disappoint market aw quick overlook
import subtl sign progress month sinc colgat
articul growth-ori strategi street chang
price target reflect premium large-cap stapl peer ep
estim
gross margin central cl invest case year miss
quarter spark bigger pictur question earn season major stapl
coverag post better expect gross margin bolster moder cost
environ posit price colgat sever outlier front gross
margin came bp vs street estim bp raw materi cost
biggest delta versu model lesser extent neg mix decad tout
gross margin key leverag point provid fund reinvest growth
colgat struggl make increment last progress front past
year sure fx input cost environ volatil recal
compani intent take gross margin bp
annual expans anyth sinc time perform stagnat see figur
 think unwis draw structur conclus singl
quarter result understand trigger question around compani longer
term abil sourc ampl reinvest dollar within return double-digit
track colgat gross margin sinc
note margin perform choppi
late although mainli driven volatil raw materi
oper environ
time improv revenu perform prior troubl spot seem
entir overlook dialogu even though isnt colgat first reinvest
year would argu first cohes coordin approach
growthraw mat price mix/oth restructuringgm chang barclay colgate-palmol
frankli re-up spend hindsight band-aid approach
restor advertis support sale cut year fx duress
ceo noel wallac plan first discuss cagni year frame strategi around
reinvigor core franchis explor new channel granular categori
opportun expand adjac time around seem yield
invest point perform hill complet overhaul
scienc diet franchis develop new e-commerc platform yield high-
singl digit revenu growth averag ttm latin america albeit versu easi
comp post organ sale growth balanc volum price wed also point
organ sale volum growth china india russia three key market
colgat suffer market share loss sale declin local special
still north america challeng exclud new skin
busi may trend rate market growth aggreg north america
organ sale quarter math half
may account pca eltamd nielsen data hasnt strong
think expect untrack channel could well make
differ particularli given preval total club channel regard
certainli appreci candid discuss brand fare sinc
relaunch domest market share bp versu
previous recal new total solv remov triclosan ingredi list
ad sensit instant odor neutral increment enamel protect
stronger fight bacteria multi-benefit formula put par crest pro-
primari competitor multi-benefit segment downsiz total
expensive/oz line health
launch even premium price point look wed expect
see similar revamp core franchis oral optic white particularli
price-ti key part go-forward strategi
chang model model organ sale growth year evenli
split volum price expect hill reflect sustain
momentum scienc diet relaunch expans intern
market look growth latin america growth africa/eurasia
expect north america includ benefit pca elta/md flow
organ sale growth year expect asia-pacif trend colgat
abl work pricing/distributor dynam china expect europ
all-in currenc expect drag top-lin growth
model net sale flattish year model gross margin bp
year expect sg includ ship handl expens bp
bp in-lin level seen last year all-in model oper
margin bp rais ep slightli lower
fx burden model organ sale continu expect gross
margin expans ep estim
lauren lieberman herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
